Skip to main content
SleepCited

CBD için Uykusuzluk

A

9 çalışmaya (1 meta-analysis, 3 RCTs), toplam 1,152 katılımcıyla dayanmaktadır. Sonuçlar çalışmalar arasında karışıktır.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dcbd\u0026condition\u003Dinsomnia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Sonuç

The evidence for CBD as a standalone remedy for insomnia is mixed — some studies show benefits while others do not, so more research is needed before it can be confidently recommended.

  • Results are mixed across 9 studies, even at Grade A evidence level due to study volume
  • A 2025 meta-analysis found inconsistent effects of cannabinoids on sleep quality
  • Some studies used medicinal cannabis blends rather than pure CBD, complicating comparisons
  • Individual responses to CBD for sleep may vary significantly

Key Study Findings

Review
Therapeutic Use of Cannabis and Cannabinoids: A Review.
Dose: None vs: None Outcome: None Etki: SMD=-0.29 (nausea/vomiting); SMD=0.57 (body weight in HIV/AIDS) None

Popülasyon: adults using cannabis or cannabinoids for medical purposes

Randomized Controlled Trial n=20 Double-blind
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised …
Dose: 10 mg THC and 200 mg CBD vs: Placebo Outcome: Total sleep time and REM sleep parameters Etki: -24.5 min TST; -33.9 min REM sleep p=0.05 (TST); p<0.001 (REM)

Popülasyon: Patients with DSM-5 insomnia disorder (16F, mean age 46.1)

Observational Study n=3118
Real-world disproportionality analysis of sleep disturbances associated with antiseizure medications in epilepsy: a pharmacovigilance study.
Dose: None vs: None Outcome: Sleep disturbance signals for ASMs in FAERS Etki: 1570 insomnia reports (most frequent) None

Popülasyon: Epilepsy patients on ASMs (FAERS Q1 2004-Q2 2025)

Cohort Study n=155 52 weeks Open-label
Opioid reduction in patients with chronic non-cancer pain undergoing treatment with medicinal cannabis.
Dose: Median 15mg THC + 15mg CBD daily vs: Opioids only (separate cohort) Outcome: Opioid consumption reduction at 12 months Etki: Median 2.7 vs 42.3 mg/day <0.05 (ITT)

Popülasyon: Chronic non-cancer pain patients on opioids

Other n=27 56 weeks Open-label
Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett …
Dose: 5-20 mg/kg/day vs: None (single-arm) Outcome: Seizure frequency reduction Etki: 66.6% had seizure reduction, 25.9% >75% None

Popülasyon: Rett Syndrome and CDKL5 patients with drug-resistant epilepsy

Randomized Controlled Trial n=30 2 weeks Double-blind
The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary …
Dose: 150 mg CBD daily vs: Placebo Outcome: Daytime neurocognitive performance Etki: None >0.05

Popülasyon: Adults with primary insomnia

Key Statistics

103

Çalışmalar

41554

Katılımcılar

Mixed

A

Derece

Referenced Papers

Clinical psychology review 2025 5 atıf
Clinical breast cancer 2025 1 atıf
Psychopharmacology bulletin 2025 1 atıf
Current psychiatry reports 2024 8 atıf
Cannabis and cannabinoid … 2023 28 atıf
Journal of primary … 2022 28 atıf
Current opinion in … 2021 15 atıf
Internal medicine journal 2020 18 atıf
Schmerz (Berlin, Germany) 2020 8 atıf
Current treatment options … 2019 20 atıf
The Medical letter … 2019
Current psychiatry reports 2017 394 atıf
Cannabis and cannabinoid … 2016 77 atıf
International journal of … 2016 16 atıf
Pharmaceuticals (Basel, Switzerland) 2012 194 atıf
Occupational medicine (Oxford, … 2012 33 atıf
The Urologic clinics … 2002 20 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

sleep:
25-150 mg, 1 hour before bed

Üst sınır: Not established; FDA max studied ~20 mg/kg/day

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Mixed --
10 mg THC and 200 mg CBD -- Negative 20
None -- Mixed 3118
Median 15mg THC + 15mg CBD daily 52 weeks Positive 155
5-20 mg/kg/day 56 weeks Positive 27
150 mg CBD daily 2 weeks Neutral 30
10 mg/kg/day CBD oral during pregnancy -- Negative --
None -- Positive 141

En iyi alım zamanı: 1 hour before bed

Safety & Side Effects

Bildirilen Yan Etkiler

  • Fatigue
  • Diarrhea
  • Changes in appetite
  • Dry mouth
  • Liver enzyme elevation at high doses

Bilinen Etkileşimler

  • CYP3A4/CYP2C19 substrates — CBD inhibits these liver enzymes
  • Blood thinners (warfarin) — CBD may increase warfarin levels
  • Clobazam — CBD significantly increases clobazam levels
  • Sedatives — additive drowsiness

Tolere edilebilir üst alım: Not established; FDA max studied ~20 mg/kg/day

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does CBD help with Uykusuzluk?
Based on 103 studies with 41,554 participants, there is strong evidence from multiple clinical trials that CBD may support Uykusuzluk management. Our evidence grade is A (Strong Evidence).
How much CBD should I take for Uykusuzluk?
Studies have used various dosages. A commonly studied range is 25-150 mg, 1 hour before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of CBD?
Reported side effects may include Fatigue, Diarrhea, Changes in appetite, Dry mouth. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for CBD and Uykusuzluk?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 103 peer-reviewed studies with 41,554 total participants. The overall direction of effect is mixed.

Related Evidence

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.